Peer-influenced content. Sources you trust. No registration required. This is HCN.
ALS News Today
“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics
Neurology March 5th 2026
Practical Neurology
“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer
Neurology February 19th 2026
Neurology Advisor
In the evolving landscape of MS treatment, the strategic choice between early aggressive and escalation therapies is critical. Understanding the nuances of patient-specific factors, such as age and disease activity, can significantly influence outcomes and guide effective management.
Neurology March 5th 2024
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS